Kyung Dong Pharmaceutical Co., Ltd.

Informe acción KOSDAQ:A011040

Capitalización de mercado: ₩170.5b

Kyung Dong Pharmaceutical Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kyung Dong Pharmaceutical.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals38.2%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera futuran/a
Cobertura de analistas

None

Última actualizaciónn/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Mar 07
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Feb 18
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Feb 03
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 19
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

Jan 04
Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

Dec 20
How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Dec 05
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Kyung Dong Pharmaceutical no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

KOSDAQ:A011040 - Estimaciones futuras de los analistas y datos financieros pasados (KRW Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
6/30/2024178,594-16,191-28,122-18,801N/A
3/31/2024170,232-18,920-24,599-16,145N/A
12/31/2023162,674-20,708-7,999-32N/A
9/30/2023165,7096,480-19,276-3,621N/A
6/30/2023174,1438,366-19,746-5,156N/A
3/31/2023173,1098,422-17,519-3,882N/A
12/31/2022182,71812,161-11,487-1,075N/A
9/30/2022181,7986,5065,8638,711N/A
6/30/2022183,6839,1797,4919,704N/A
3/31/2022185,79312,2918,96211,526N/A
12/31/2021177,61112,6727,68512,422N/A
9/30/2021175,89413,577-19,9914,049N/A
6/30/2021172,33211,669-14,2929,512N/A
3/31/2021171,85311,087-21,7386,344N/A
12/31/2020173,82812,459-11,24417,116N/A
9/30/2020175,09112,91611,63218,460N/A
6/30/2020174,26318,5493,0619,961N/A
3/31/2020176,34820,78811,07313,359N/A
12/31/2019176,50020,126-4,196-2,781N/A
9/30/2019175,9065,751-1892,050N/A
6/30/2019177,8423,1559,61512,950N/A
3/31/2019175,6023,19312,19115,589N/A
12/31/2018179,3165,24229,50433,268N/A
9/30/2018180,11216,91228,15033,220N/A
6/30/2018181,52818,70024,86528,864N/A
3/31/2018181,86120,562N/A27,990N/A
12/31/2017177,77220,477N/A14,788N/A
9/30/2017173,02222,222N/A19,863N/A
6/30/2017166,64019,444N/A19,176N/A
3/31/2017162,70318,670N/A18,588N/A
12/31/2016158,59917,609N/A25,628N/A
9/30/2016155,70518,629N/A24,324N/A
6/30/2016153,07913,673N/A23,802N/A
3/31/2016150,79313,928N/A21,205N/A
12/31/2015151,89314,132N/A18,257N/A
9/30/2015153,19515,395N/A15,456N/A
6/30/2015151,28822,404N/A17,088N/A
3/31/2015153,28622,924N/A20,430N/A
12/31/2014153,26024,518N/A23,130N/A
9/30/2014151,58123,891N/A25,401N/A
6/30/2014148,23625,787N/A22,025N/A
3/31/2014140,86324,591N/A15,381N/A
12/31/2013133,07418,852N/A16,423N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if A011040's forecast earnings growth is above the savings rate (2.6%).

Beneficios vs. Mercado: Insufficient data to determine if A011040's earnings are forecast to grow faster than the KR market

Beneficios de alto crecimiento: Insufficient data to determine if A011040's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if A011040's revenue is forecast to grow faster than the KR market.

Ingresos de alto crecimiento: Insufficient data to determine if A011040's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if A011040's Return on Equity is forecast to be high in 3 years time

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y